Clinical TrialJul 17, 2026, 10:45 AM
Compass Therapeutics to Present Phase 2/3 Trial Results at ESMO
AI Summary
Compass Therapeutics announced that its abstract for the COMPANION-002 clinical trial has been accepted for an oral Proffered Paper presentation at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026. The presentation will highlight results from the randomized, controlled Phase 2/3 trial assessing tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer. Dr. Nilofer Azad will present the findings on October 24, 2026.
Key Highlights
- Abstract accepted for oral Proffered Paper presentation at ESMO Congress.
- Presentation highlights results of randomized Phase 2/3 COMPANION-002 clinical trial.
- Trial assesses tovecimig (DLL4 x VEGF-A bispecific antibody) with paclitaxel.
- Focus is on previously treated patients with advanced biliary tract cancer (BTC).
- Presentation by Dr. Nilofer Azad on October 24, 2026, 10:15am – 11:45am CET.
Price Impact
More from CMPX